Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Radiation therapy in prostate cancer

This article was originally published in Clinica

Executive Summary

Treatment of early-stage prostate cancer with external beam radiation therapy (EBRT) carries a lower risk of subsequent impotency than nerve-sparing surgery, a new study shows. The findings, presented at the annual meeting of the American Society for Therapeutic Radiology and Oncology (ASTRO) in Florida this month, showed that EBRT for patients aged 50 to 69 years resulted in slightly lower impotency rates than nerve-sparing surgery in patients of the same age range.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT093881

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel